Financials
- Fiscal year
- 2024
- Total assets
- €63,724
- Loss
- -€3,253
- Solvency
- 60.6%
Turnover▼ 18.7%
Net result
20192023
S.C. Pharma
ActiveSummary
The computed 12-month bankruptcy probability of S.C. Pharma is 2.8% (moderate). The 2024 annual accounts show equity of €38,607 and a net result of -€3,253. Equity is growing by ~6.1% per year across the filed fiscal years. The company has been active since 2018 and the Belgian State Gazette contains no insolvency or warning signals.
Overview
What they do
Retail sale of pharmaceutical products
NACE 47730
1 site
How big
€63,724total assets 2024
- Equity
- €38,607
- Loss
- -€3,253
Turnover not published (abridged schema)
Who decides
Accounts 44 d early0 of 4 deeds read
Why 51- Figures for FY 2024 (filed 03-07-2025)- Founded in 2018- Loss of €3,253 (FY 2024)+ Equity €38,607 (60.6% of total assets)Show the evidence
Checked score
Score 2024
51
/ 100
Fair
Probability in this band: 1.5% to 4.2%
Better than 45% of its sector peers (NACE 47, micro)
Performance against the sector, not lower risk
Financial strength · tick = 2023
Strong
Solvency
86+6
equity 60.6% of total assets
Liquidity
37-19
short-term debt 39.4% · cash 4.6%
Profitability
62-27
return on assets -5.1%
Bankruptcy probability, 12 months
2.8%
Moderate
0%0.5%1.5%4%10%≥ 25%
About 3 in 100 comparable companies go bankrupt within 12 months (an estimate).
- Figures for FY 2024 (filed 03-07-2025) raises the probability
- Founded in 2018 raises the probability for this profile
- Loss of €3,253 (FY 2024) raises the probability
- Equity €38,607 (60.6% of total assets) lowers the probability
Credit up to €1,500 at 30 days acceptable
Liquidity short (current ratio 0.43 against 0.23 in 2023; short-term debt: 39.4% and cash: 4.6% of total assets), and 39.4% of the assets are financed with debt.
How it is calculated
The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 47, micro). Better than this share of them on solvency 73%, liquidity 35%, profitability 44%, growth against the median 28%. That is performance, not lower risk; the band itself always comes from the probability.
Bankruptcy probability: model pd-v3.202610021621, computed on 02-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.
Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 17-06-2026, 44 days ahead of the deadline.
NBB · 7 filingsDeviation from the deadline
2025
44 d early
2024
35 d early
2023
35 d early
2022
33 d early
2021
53 d early
2020
25 d early
2019
51 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 39 days before the deadline; the sector median for financial year 2024 is on the deadline day, and 47% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 26 June (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsPosition in the running window
02-10-2026 today31-12-2026 close31-07-2027 deadline
- Annual accounts filedfiscal year 2025 · micro…
- Annual accounts filedfiscal year 2024 · micro…
- Weakest financial yearnet -€3,253
Key points
By topic
Timeline
- Events
- 9
- Since
- 2020
- Next accounts
- by 31-07-2027
- 17-06-2026Annual accounts filed
- 26-06-2025Annual accounts filed
- 31-12-2024Weakest financial year
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Founded
- 17-08-2018
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.